Eli Lilly's obesity pill shows promise for sleep apnoea treatment
Summarised from 2 outlets · Updated 10 Nov, 04:13 · Archive
Eli Lilly's obesity pill Foundayo significantly reduced sleep apnoea severity in a late-stage trial, with plans to seek US approval by year end.
Eli Lilly announced that its obesity pill Foundayo significantly reduced the severity of obstructive sleep apnoea in a late-stage trial. The company plans to file for US approval of the daily pill for moderate-to-severe sleep apnoea in adults with obesity or who are overweight by the end of the year.
Obstructive sleep apnoea refers to interrupted breathing during sleep due to narrowed or blocked airways, which can cause drops in oxygen and increases in blood pressure associated with serious complications including hypertension, heart failure and stroke. The condition affects an estimated eight million Britons and nearly one billion adults globally. Most have never been diagnosed.
Patients taking Foundayo experienced around 18 fewer breathing interruptions an hour, as well as significant improvements in blood pressure, oxygen levels and sleep quality. The trial tested Foundayo in two independent studies. Many patients currently rely on continuous positive airway pressure machines, which deliver air through a mask worn at night, but nearly half either refuse to use them or stop wearing them due to discomfort.
Foudayo rolled out in the US in April. Lilly's injectable weight-loss drug Zepbound became the first medication to win US approval for obstructive sleep apnoea in December 2024.

How it is being reported
- Weight-loss pill that could transform treatment for millions with a common 'snoring' condition linked to heart attacks and strokes... and mean an end to uncomfortable night-time breathing masksMillions of sleep apnoea sufferers could one day ditch bulky breathing machines in favour of a daily weight loss pill.Daily Mail · 9 Nov, 16:30
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approvalLilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity.CNBC · 9 Nov, 14:30
In this story: Eli Lilly · Foundayo · Zepbound · United States
This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log
Comments (0)